Corcepttherapeutics
Director, Oncology Clinical Affairs (MD)
United States. Posted 2 months ago
The role
This person will serve as a senior clinical associate within Oncology to lead high-level clinical and scientific engagement with external oncology experts. They will help shape and execute the introduction of Lifyorli in clinical practice with a primary focus in the US market.
What you will do
- Partner with Medical Affairs leadership to support medical priorities related to product adoption.
- Serve as the primary clinical bridge between Clinical Development and go-to-market teams.
- Provide clinical and medical/scientific expertise for tactical planning, advisory boards, and congress activities.
- Identify areas of unmet medical need to translate scientific insights into clinical guidance.
- Lead high-level peer-to-peer scientific interactions with oncology experts and key opinion leaders.
- Engage physicians through advisory boards, congress interactions, and speaker preparation.
- Represent Corcept at key medical conferences and external events.
- Provide clinical input to post-approval evidence generation activities like real-world evidence and investigator sponsored studies.
- Provide perspectives in interpreting and influencing clinical guideline updates and treatment pathways.
- Partner with Pharmacovigilance to develop and communicate safety-related clinical guidance.
Required qualifications
- MD required
- Oncology experience required
- 3-5+ years of relevant oncology practice (including fellowship)
- Experience engaging oncology experts, interpreting clinical evidence, and translating complex data into clear scientific and clinical communications
Nice to have
- gynecologic oncology experience
Before you apply
- Applicants must be currently authorized to work in the United States on a full-time basis.
About the company
Corcept is focused on the science of cortisol to address diseases. The company has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists.